Participated · Seed · Apr 2026

Fermeate develops an optogenetics platform that uses light-sensitive proteins and AI-driven light patterns to control gene expression in microbial fermentation processes. The technology can be retrofitted into existing stainless-steel fermenters by recirculating culture through an external light-delivery device, enabling higher and more sustained productivity. Founded in 2024 by Kevin Xu, PhD, and Saurabh Malani, PhD, the company has partnerships with four global food and ingredient companies and reports up to a 200% increase in protein production in under six months, with potential for up to 10x gains. Fermeate has validated its approach on multiple industrial host strains, including conventional and non-conventional yeasts and bacteria. The company is generating revenue through several paid projects while exploring business models and aims to scale its tech to improve capital efficiency across biomanufacturing operations.

Participated · Series A · Mar 2024

HarvestX develops an automated strawberry cultivation solution that combines robotics, AI, optimized racks and cultivation recipes to automate plant management and pollination. Its core product is the HarvestX system centered on the XV3 pollination robot, composed of an XV3 Cart and XV3 Unit for sensing and robotic work. The company says XV3 achieved the world’s first robotic strawberry pollination (patent no. 7090953) and has completed in-house trials and introduction experiments with plant factory operators. HarvestX plans to build a demo pilot plant (first phase due May 2024), add harvesting functionality in 2025, and target expansion to other pollination-dependent fruit crops such as tomato and melon. Founded as a University of Tokyo spinout in 2020 and based in Bunkyo, Tokyo, HarvestX will use the recent funding to advance R&D and commercial piloting of its solution. After the round and a municipal grant, the company’s disclosed total funding is ¥610 million.

Participated · Series C · Feb 2020

Hinge Health offers a digital MSK care platform that combines advanced wearable sensors and computer vision with monitoring by a clinical care team of physical therapists, physicians, and board-certified health coaches. The company aims to reduce MSK pain, surgeries, and opioid use while improving patient outcomes and experiences. The new capital will be directed toward technology and product development to improve access, outcomes and patient experiences, according to CEO Daniel Perez. Hinge Health says it is now one of the most valuable companies in digital health. The company has more than doubled its customer base this year to serve over 575 enterprise customers and is approaching 1,000 employees. Total capital raised to date is over $1 billion, including the latest round at a $6.2 billion valuation. Hinge Health offers a digital solution for chronic musculoskeletal (MSK) conditions, combining wearable sensors, a mobile app and health coaching to deliver remote physical therapy and behavioral health. The platform is primarily sold to U.S. employers and health plans. Hinge positions its technology and data to improve treatment adherence and reduce reliance on opioid-based painkillers and surgery. The company was originally based in London and is now described as San Francisco-based. Hinge reported a 300% increase in revenue in 2020 and investors were told revenue was expected to nearly triple again in 2021 based on its booked pipeline. Founders Daniel Perez and Gabriel Mecklenburg remain in voting control of the board. Hinge Health delivers remote physical therapy and behavioral health for chronic musculoskeletal conditions via wearable sensors, a patient-facing app, and a large clinical coaching team. The company sells primarily into U.S. employers and health plans and emphasizes outcomes and engagement to drive enterprise adoption. Hinge reports clinical and commercial outcomes including avoiding two-thirds of elected surgeries, delivering a 3–4x ROI across its book of business, and helping four in five participants achieve meaningful pain reduction (average pain reduction of 69%). The company also reports cutting anxiety and depression rates by more than half among participants. Hinge has grown its enterprise customer base threefold in six months to roughly 200 implementations and maintains 100% customer retention; it says four in five employers with a digital MSK solution have bought Hinge. Headcount is about 225 with plans to expand to over 400 in the next 12–18 months and to move to larger San Francisco offices within months. Hinge Health combines wearable motion sensors, a mobile app, and one-to-one health coaching to remotely deliver physical therapy and behavioral health for chronic MSK conditions. The company positions itself as a “Digital Care Pathway,” emphasizing active patient participation rather than a passive “digital therapeutic.” Its initial commercial targets are self-insured employers and health plans, and it reports 40 enterprise customers in the U.S. and partnerships with 10 of the largest health plans. Clinical outcomes have improved: two in three patients who go through the program avoid the need for surgery (up from one in two at Series A), and the company aims to increase that to 80 percent. Founded in 2015 and originally based in London, Hinge Health is now San Francisco–based and its founders, Daniel Perez and Gabriel Mecklenburg, retain majority control of the board. The company has raised capital to scale its offering and commercial partnerships while continuing to refine its care model and adherence tools. Hinge Health builds “Digital Care Pathways” to remotely treat musculoskeletal (MSK) disorders by combining wearable sensors, a patient app, health coaching, peer support and cognitive behavioral therapy. The platform targets chronic conditions (e.g., back, knee, shoulder pain) and is designed to increase adherence and deliver evidence-based therapy outside traditional acute-care systems. The company reports data on over 1,000 patients, showing a 55% improvement in chronic lower back and knee pain, avoidance of 60% of surgeries, and 80% adherence through 12 weeks. Hinge Health recently completed a randomized controlled trial and plans to publish the results later in the year. Its commercial strategy targets self-insured employers and health plans in the U.S., pitching material reductions in MSK-related medical costs. The broader vision is to expand beyond MSK into additional conditions and ultimately create a “digital hospital” of scalable, evidence-based care pathways; the company was founded out of London and has since moved its headquarters to San Francisco.

Participated · Seed · Dec 2018

Bios develops neural interface technologies that combine hardware, big data and machine learning/AI to pursue new treatments across organs and nerve systems. The company is based in Cambridge, U.K., and also maintains an R&D office in Montreal, Canada. Bios was co-founded by Emil Hewage and Oliver Armitage. In May 2018 the company raised $4.5m in seed funding to support its development. The funds are intended to scale its technical team and further develop its core neural interface technologies. Investors in the round include several venture firms and angels co-leading and participating in the seed round.

Participated · Seed · Dec 2018

BIOS Health develops an AI-driven brain data and neural digital therapy platform that identifies neural biomarkers to connect nerve activity with specific illnesses. The company focuses on leveraging nervous-system data to create neural digital therapies and accelerate precision medicine for conditions such as hypertension, diabetes, rheumatoid arthritis, Parkinson’s and Alzheimer’s. BIOS positions its technology as a way to codify the "neural code" and enable a new generation of medicines and data-driven clinical trials. The firm says it will use the new funds and revenue growth to build market share. BIOS was founded in 2015 by Cambridge University researchers Emil Hewage and Oliver Armitage and its team spans neuroscience, machine learning, software, applied biomaterials, biotech and medicine. Earlier this year the NIH and institutions including the University of Minnesota, the Mayo Clinic, and Stanford chose BIOS’ technology to power the three-year, eight-clinic REVEAL programme, described by BIOS as the largest clinical investigation of human brain data to date. BIOS Health is developing an AI-controlled closed-loop neuromodulation system aimed at treating chronic cardiac conditions by linking neural and cardiac signals. The company collaborates with academic partners including Mila, McGill University and Université de Montréal, and works closely with researchers Dr. Blake Richards and Dr. Guillaume Lajoie. Its work focuses on using machine learning to decode neural‑to‑cardiac relationships and identify neural biomarkers that enable personalized, second-by-second modulation of cardiac function. The technology aims to preferentially modulate cardiac activity while reducing side effects on other organs, potentially replacing some pharmaceutical interventions. BIOS plans to advance the program toward human clinical trials, with the CEO stating the next stage will take the project up to the point of clinical testing. The company’s research programme began with a CA$800,000 partnership launched in 2020 and is being expanded through new, project-specific funding. BIOS is developing a core neural interface product and related AI that the company says can connect to organs and nerve systems across the body. Its first product, described as a “USB connector for the body,” enabled a Prosthetic Interface Device (PID) that lets amputees connect prostheses directly to the nervous system and is about to enter clinical trials. R&D has produced safer, more accurate hardware and yielded a large neural data set that BIOS uses to train its algorithms. The company plans to both build some products itself and partner with commercial and academic organisations, expanding access via tools, data sets and algorithms for discovering neural biomarkers. BIOS is originally based in Cambridge, U.K., and has opened an additional R&D office in Montreal, Canada. The startup will use the funding to double its technical team and further develop its core neural-interface technologies while helping push industry standards and formats for neural data.